3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Neoplasms
8
Carcinoma, Non-Small-Cell Lung
4
Neoplasm Metastasis
3
Melanoma
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Glioblastoma
2
Central Nervous System Neoplasms
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Adenocarcinoma
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Interventions
Gemcitabine
12
Cisplatin
11
pembrolizumab
6
Docetaxel
5
Capecitabine
5
camrelizumab
4
Injections
4
toripalimab
3
spartalizumab
3
penpulimab
2
famitinib
2
SHR-1701
2
Carboplatin
2
18-O-demethylcervinomycin A2
2
tislelizumab
1
icotinib
1
donafenib
1
cc-486
1
Valganciclovir
1
Radiotherapy, Intensity-Modulated
1
Quality of Life
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Medicare Part B
1
Ipilimumab
1
Immunotherapy
1
Fluorouracil
1
Drug Therapy
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Nasopharyngeal Carcinoma
×
Immunotherapy
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled